Skip to content

Steve Garland

  • CEO/Founder
  • NQuiX Ltd
  • 10h-indexImpact measure calculated using publication and citation counts. Updated daily.
  • 469CitationsNumber of citations received by Steve's publications. Updated daily.

Recent publications

  • Corrigendum to "(1H-Imidazo[4,5-c]pyridin-2-yl)-1,2,5-oxadiazol-3-ylamine derivatives: A novel class of potent MSK-1-inhibitors" [Bioorg. Med. Chem. Lett. 15 (2005) 3402-3406]

    • Bamford M
    • Alberti M
    • Bailey N
    • et al.
    N/AReaders
    N/ACitations
    Get full text
  • Erratum: What is the potential of G protein-coupled receptor allosteric sites in drug design? (Future Medicinal Chemistry (2014) 6:7 (729-732))

    • Garland S
    N/AReaders
    N/ACitations
    Get full text

Professional experience

CEO/Founder

NQuiX Ltd

August 2011 - Present

Group Leader, Lead Generation

GlaxoSmithKline

December 2008 - August 2011(3 years)

Manager, 7TM Systems Modelling Group

GlaxoSmithKline

Computational Chemist

GlaxoSmithKline

RPR Research Fellow

University of Cambridge

Education

PhD

University of Cambridge

BA (Hons)

Oxford University

Research interests

GPCR Drug Discovery Protein-Protein Interactions Lead Generation Computational Chemistry Cheminformatics Chemogenomics

Co-authors (82)

  • David Gloriam

Other IDs